Results 181 to 190 of about 229,703 (354)

Gut microbiota‐related modulation of immune mechanisms in post‐infarction remodelling and heart failure

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 942-954, April 2025.
Abstract The immune system has long been recognized as a key driver in the progression of heart failure (HF). However, clinical trials targeting immune effectors have consistently failed to improve patient outcome across different HF aetiologies. The activation of the immune system in HF is complex, involving a broad network of pro‐inflammatory and ...
Johann Roessler   +4 more
wiley   +1 more source

Clinical impact of follow‐up endomyocardial biopsy in myocarditis during or after immune‐suppressive therapy

open access: yesESC Heart Failure, EarlyView.
Results and clinical implication of repeat endomyocardial biopsy (EMB). Abstract Aims While the diagnostic role of endomyocardial biopsy (EMB) in myocarditis is unquestioned, little is known about its indications and clinical value during long‐term follow‐up.
Anna Baritussio   +12 more
wiley   +1 more source

A novel myeloid cell in murine spleen defined through gene profiling [PDF]

open access: yes, 2019
Dabiri GA   +5 more
core   +1 more source

Immune dysregulation as a key driver of peripartum cardiomyopathy – an exploratory advanced imaging and biomarker study

open access: yesEuropean Journal of Heart Failure, EarlyView.
Physiological postpartum remodelling and the pathological processes involved in peripartum cardiomyopathy (PPCM). 18FDG‐PET‐CT, 18F‐fluorodeoxyglucose positron emission tomography‐computed tomography; CCL3, chemokine (C‐C motif) ligand 3; CMR, cardiovascular magnetic resonance; CRP, C‐reactive protein; CSF‐1, colony‐stimulating factor 1; CXCL10 ...
Julian Hoevelmann   +14 more
wiley   +1 more source

Home - About - Disclaimer - Privacy